Klinikum der Universität München-ko ikertzaileekin lankidetzan egindako argitalpenak (1)

2020

  1. Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumours

    British Journal of Cancer, Vol. 122, Núm. 9, pp. 1324-1332